archive-com.com » COM » E » ENDEAVOURVISION.COM

Total: 462

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Recent news: FierceBiotech names Molecular Partners as one of its “Fierce 15” Biotech Companies of 2014
    of its Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs Zurich Schlieren September 22 2014 Molecular Partners today announced that it has been named by FierceBiotech as one of 2014 s Fierce 15 biotechnology companies designating it as one of the most promising private biotechnology companies in the industry In an environment where so many biotechs are looking for a quick exit to please their investors it s refreshing to see a company working to lay down roots and stick around for the long haul says Damian Garde editor of FierceBiotech And Molecular Partners is going about it practically doubling down on a validated platform as it expands its pipeline Molecular Partners is a clinical stage biopharmaceutical company developing DARPins a new class of

    Original URL path: http://www.endeavourvision.com/news-n237-c0-s22-FierceBiotech+names+Molecular+Partners+a.htm (2016-04-25)
    Open archived version from archive


  • Recent news: Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo™, and Launches Product With First Commercial Implantations
    names Molecular Partners as one of its Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs Symetis Joins Industry Leaders Edwards Lifesciences and Medtronic as Only Companies to Offer Both Transapical and Transfemoral Options for Transcatheter Aortic Heart Valve Delivery LAUSANNE SWITZERLAND Marketwired Sept 12 2014 Symetis SA the leading European developer of transcatheter aortic valve implantation TAVI systems announced today the launch of ACURATE neo its 15F compatible transfemoral TAVI system Commercial implantations started early September after Symetis received CE Mark approval for ACURATE neo this summer Symetis conducted a single arm prospective multicenter trial at six centers of excellence in Brazil Germany and Japan enrolling 89 high risk patients with severe symptomatic aortic stenosis who were considered high risk or non surgical candidates

    Original URL path: http://www.endeavourvision.com/news-n234-c0-s22-Symetis+Receives+CE+Mark+Approval+for+Tr.htm (2016-04-25)
    Open archived version from archive

  • Recent news: Sophia Genetics Becomes the First European Company to Obtain CE-IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing
    Partners as one of its Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs LAUSANNE Switzerland September 2 2014 PRNewswire Shortly after receiving ISO 13485 accreditation Sophia Genetics has become the first European company to obtain a CE IVD mark for the clinical use of a Next Generation Sequencing NGS bioinformatic pipeline for routine genetic testing This quality assurance certification represents an important step in raising the standards of routine genetic testing and clinical diagnosis and brings Sophia Genetics world leading Data Driven Medicine platform to a wider market The certification also means that Sophia Genetics proven quality assurance methodology can now be leveraged by clinical laboratories to meet their own quality assurance requirements Using Sophia Genetics service clinical laboratories gain access to quality assurance

    Original URL path: http://www.endeavourvision.com/news-n230-c0-s22-Sophia+Genetics+Becomes+the+First+Europe.htm (2016-04-25)
    Open archived version from archive

  • Recent news: Sophia Genetics raises Series B round led by Invoke Capital
    one of its Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs Investment Aims to Accelerate European Adoption of Clinical Analytics for Genetic Diseases London UK and Lausanne Switzerland 8th July 2014 Sophia Genetics the European leader in Data Driven Medicine has raised 13 75M in Series B financing in a round led by Dr Mike Lynch s Invoke Capital Endeavour Vision and Swisscom Sophia Genetics is a pioneer in Data Driven Medicine a crossover field that requires deep expertise in Next Generation Sequencing NGS combined with highly accurate and scalable predictive algorithms to diagnose genetic diseases With this investment Sophia gains access to Invoke s portfolio company Genalys whose Cambridge based mathematicians apply big data approaches to genomic information The combination means that clinicians

    Original URL path: http://www.endeavourvision.com/news-n228-c0-s22-Sophia+Genetics+raises+Series+B+round+le.htm (2016-04-25)
    Open archived version from archive

  • Recent news: Stage 3 Phase 2 study of DARPin abicipar pegol (previously MP0112) supports progressing to phase III development program
    of its Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs Zürich Schlieren Switzerland July 01 2014 Molecular Partners AG announced today results from the Allergan sponsored double masked stage 3 phase 2 study of the DARPin abicipar pegol for wet age related macular degeneration AMD The results demonstrate that abicipar pegol provides equal or potentially higher vision gains compared to ranibizumab Lucentis with fewer injections Further Allergan announced that full phase III development is anticipated to start in Q2 of 2015 Abicipar pegol previously AGN 150998 or MP0112 is a long acting potent antagonist of vascular endothelial growth factor VEGF which is based on the DARPin technology Abicipar pegol was licensed to Allergan from Molecular Partners in May 2011 Christian Zahnd CEO of Molecular

    Original URL path: http://www.endeavourvision.com/news-n227-c0-s22-Stage+3+Phase+2+study+of+DARPin+abicipar.htm (2016-04-25)
    Open archived version from archive

  • Recent news: Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant
    Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs By Chris Reidy GLOBE STAFF JUNE 19 2014 Bind Therapeutics Inc a Cambridge based nanomedicine company that is developing programmable drugs to certain types of cancer said Thursday it has entered into a research agreement with Swiss drug giant Roche to discover novel treatment of diseases in therapeutic areas outside of oncology Financial terms of the collaboration are not being disclosed Bind Therapeutics is developing Accurins In simple terms Accurins are a precise delivery platform designed to target specific cells or tissues and concentrate a drug payload at the site of disease while minimizing adverse effects on healthy tissues The plan of the collaboration is to combine Bind s Accurin nanomedicine delivery technology with Roche drug

    Original URL path: http://www.endeavourvision.com/news-n226-c0-s22-Bind+Therapeutics+enters+nanomedicine+co.htm (2016-04-25)
    Open archived version from archive

  • Recent news: CeQur Appoints Douglas Lawrence Chief Executive Officer
    one of its Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs Experienced Medical Device Executive Will Lead Company Through Scale Up and International Commercialization of PaQ Insulin Delivery Device HORW Switzerland April 10 2014 PRNewswire CeQur SA a leader in simple insulin infusion for people with type 2 diabetes announced the appointment of Douglas Lawrence as chief executive officer effective immediately Lawrence replaces CeQur founder James Peterson who is retiring from the role but will continue to serve as vice chairman of the CeQur Board of Directors Lawrence brings more than 25 years of medical device and pharmaceutical industry experience at category leading companies including Procter Gamble and The BOC Group Over the past 15 years he has held positions of increasing scope and

    Original URL path: http://www.endeavourvision.com/news-n220-c0-s22-CeQur+Appoints+Douglas+Lawrence+Chief+Ex.htm (2016-04-25)
    Open archived version from archive

  • Recent news: Epigenetic Cancer Therapy Clears Phase I
    Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs Investigational drug that inhibits proteins involved with epigenetic regulation shows activity against certain blood cancers in an early stage clinical trial By Tracy Vence April 7 2014 on www the scientist com A new therapy designed to treat cancer by regulating gene expression has helped a handful of patients with blood malignancies in a preliminary clinical trial according to pharmaceutical company Oncoethix Today April 7 at the American Association for Cancer Research AACR annual meeting in San Diego California the Lausanne Switzerland based firm presented unpublished data from a Phase I clinical trial of the drug OTX015 a small molecule inhibitor of the BET bromodomain proteins BRD2 BRD3 and BRD4 which help to regulate gene expression

    Original URL path: http://www.endeavourvision.com/news-n218-c0-s22-Epigenetic+Cancer+Therapy+Clears+Phase+I.htm (2016-04-25)
    Open archived version from archive



  •